Scientists have created different versions of a molecule that can selectively lock Ras in either its active or inactive form, or bind both forms equally, allowing precise control over how the protein functions in cancer cells.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether inhibitors designed to target active-state Ras improve clinical outcomes more than inactive-state inhibitors in patients with specific KRas mutations.
A systematic review and meta-analysis of all clinical trials comparing active-state vs. inactive-state Ras inhibitors in patients with KRas-mutant cancers, evaluating overall survival, response rates, and resistance patterns stratified by mutation subtype and inhibitor binding profile.
Whether active-state vs. inactive-state inhibitors produce different clinical responses in patients with KRas-mutant cancers.
A double-blind, randomized phase II trial of 120 patients with KRasG12D or KRasG12V mutations, randomized to receive either an active-state binder or an inactive-state binder for 24 weeks, with primary endpoint of tumor response by RECIST 1.1 and secondary endpoints of pERK suppression and progression-free survival.
Whether patients treated with active-state Ras inhibitors show different patterns of resistance or biomarker response compared to those treated with inactive-state inhibitors.
A prospective cohort study of 200 patients with KRas-mutant cancers receiving either active-state or inactive-state inhibitors as part of clinical trials, tracking resistance mechanisms via serial ctDNA analysis and pERK dynamics over 18 months.
Whether tumors that develop resistance to active-state inhibitors have different molecular profiles than those resistant to inactive-state inhibitors.
A matched case-control study comparing 50 tumors with acquired resistance to active-state inhibitors to 50 tumors with resistance to inactive-state inhibitors, analyzing genomic, transcriptomic, and phosphoproteomic profiles for distinct resistance signatures.
Whether active-state inhibitors reduce pERK levels more effectively than inactive-state inhibitors in tumor biopsies from patients with KRas mutations.
A cross-sectional analysis of pre-treatment and 24-hour post-dose tumor biopsies from 60 patients with KRas-mutant cancers treated with either an active-state or inactive-state inhibitor, measuring pERK suppression by immunohistochemistry and Western blot.